Balyasny Asset Management L.P. Sells 10,575 Shares of Astrana Health, Inc. (NASDAQ:ASTH)

Balyasny Asset Management L.P. cut its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 53.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,384 shares of the company's stock after selling 10,575 shares during the quarter. Balyasny Asset Management L.P.'s holdings in Astrana Health were worth $296,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pilgrim Partners Asia Pte Ltd bought a new stake in Astrana Health in the 4th quarter worth about $40,000. Quarry LP increased its holdings in Astrana Health by 35.5% in the 4th quarter. Quarry LP now owns 1,799 shares of the company's stock worth $57,000 after buying an additional 471 shares in the last quarter. KBC Group NV increased its holdings in Astrana Health by 108.4% in the 4th quarter. KBC Group NV now owns 2,530 shares of the company's stock worth $80,000 after buying an additional 1,316 shares in the last quarter. US Bancorp DE increased its holdings in Astrana Health by 3,880.0% in the 4th quarter. US Bancorp DE now owns 4,776 shares of the company's stock worth $151,000 after buying an additional 4,656 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its holdings in Astrana Health by 21.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 7,075 shares of the company's stock worth $223,000 after buying an additional 1,273 shares in the last quarter. 52.77% of the stock is currently owned by institutional investors.

Astrana Health Price Performance

ASTH traded down $0.18 on Friday, hitting $24.29. 254,478 shares of the company's stock traded hands, compared to its average volume of 290,686. The company's 50 day simple moving average is $30.34 and its 200-day simple moving average is $34.41. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 18.68, a P/E/G ratio of 1.37 and a beta of 1.00. Astrana Health, Inc. has a one year low of $23.12 and a one year high of $63.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.09). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $620.39 million for the quarter, compared to the consensus estimate of $628.11 million. During the same period last year, the business posted $0.31 EPS. The firm's revenue for the quarter was up 53.4% compared to the same quarter last year. As a group, research analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Stifel Nicolaus dropped their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Bank of America dropped their target price on Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Barclays assumed coverage on Astrana Health in a research report on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 target price on the stock. Robert W. Baird dropped their target price on Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Finally, Truist Financial dropped their target price on Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a research report on Tuesday, March 18th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $53.29.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.